MapLight Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from MapLight Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-155.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 89% of Healthcare companies in United States.
Cash Cushion Ratio
+65%Cash, after subtracting all debt, equals 65% of its market value (net cash).
Higher than 82% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
MapLight Therapeutics, Inc. made a loss over the last year. MapLight Therapeutics, Inc. owes $0.05 for every $1 it owns.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMapLight Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.32The share price is 1.32 times MapLight Therapeutics, Inc.'s book value per share, lower than 72% of Healthcare companies in United States.
Market cap
$458 MThe total market value of all of MapLight Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$348 MWhat MapLight Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.27Net worth divided by the number of shares. The share price of $8.25 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-111.5%MapLight Therapeutics, Inc. lost 111.5% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
Owes vs Owns
0.05×MapLight Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneMapLight Therapeutics, Inc. does not currently pay a dividend.
Cash vs debt
Net cashMapLight Therapeutics, Inc. held $299 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For MapLight Therapeutics, Inc.: $458 M ÷ $348 M (30 Jun 2026) = 1.3.
What is MapLight Therapeutics, Inc.'s return on equity?
MapLight Therapeutics, Inc. lost 111.5% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
How much does MapLight Therapeutics, Inc. owe compared with what it owns?
MapLight Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does MapLight Therapeutics, Inc. pay a dividend?
No. MapLight Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.